GlassScriptPhysician profile
Shreeniwas Lele
NPI 1568568426
$15,830.77
in general payments reported to CMS, 2019-2025
67 companies · $2,976 in 2025
The $2,976 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,402 · 2020: $1,207 · 2021: $2,065 · 2022: $1,114 · 2023: $2,713 · 2024: $3,353 · 2025: $2,976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,931 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,930.52 |
| Education | $112.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,131.96 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,294.93 | 2019-2025 | |
| Novo Nordisk INC | $1,186.52 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,034.51 | 2019-2025 | Repatha, Evenity, Prolia |
| Lilly USA, LLC | $778.38 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $760.87 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $754.42 | 2019-2025 | Jardiance, Synjardy |
| Pfizer INC. | $730.53 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $496.76 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astellas Pharma US INC | $438.02 | 2019-2025 | Veozah, Myrbetriq |
| Lundbeck LLC | $314.28 | 2023-2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $309.46 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Otsuka America Pharmaceutical, INC. | $298.75 | 2021-2025 | Rexulti, Nuedexta |
| Sanofi-Aventis U.S. LLC | $289.61 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $283.35 | 2019-2025 |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $276.33 | 2020-2025 | Eliquis, Cobenfy |
| Abbott Laboratories | $271.33 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $254.80 | 2021-2024 | |
| Corcept Therapeutics | $244.87 | 2024-2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $218.57 | 2019-2024 | Xifaxan, Cycloset |
| Teva Pharmaceuticals USA, INC. | $217.89 | 2019-2025 | Austedo Xr, Austedo Xr |
| Phathom Pharmaceuticals, INC. | $210.44 | 2024-2025 | Voquezna |
| Allergan, INC. | $208.62 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $196.74 | 2019-2024 | Spravato, Xarelto |
| Sunovion Pharmaceuticals INC. | $188.28 | 2019-2022 | |
| Axsome Therapeutics, INC. | $172.20 | 2023-2025 | Auvelity |
| Mylan Specialty L.P. | $162.62 | 2019-2024 | Yupelri |
| Mannkind Corporation | $144.20 | 2025 | |
| Sumitomo Pharma America, INC. | $141.77 | 2023-2025 | Gemtesa |
| Vivus LLC | $129.09 | 2019-2025 | Qsymia |
| Aimmune Therapeutics, INC. | $124.67 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $112.58 | 2020-2023 | |
| Amarin Pharma, INC. | $105.19 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $105.02 | 2023-2025 | Caplyta |
| Hikma Pharmaceuticals USA | $103.06 | 2019-2022 | |
| Dexcom, INC. | $100.96 | 2023-2025 | Dexcom G6 Transmitter |
| Radius Health, INC. | $90.75 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $77.19 | 2019-2025 | Trintellix |
| Beta Bionics, INC. | $71.97 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Biohaven Pharmaceutical Holding Company LTD. | $65.37 | 2022 | |
| Evoke Pharma, INC. | $63.19 | 2023-2024 | Gimoti |
| Boston Scientific Corporation | $61.05 | 2025 | Wavewriter Alpha Prime 16, Watchman Flx |
| Kowa Pharmaceuticals America, INC. | $51.24 | 2021-2025 | Zoryve |
| Esperion Therapeutics, INC. | $48.66 | 2021-2023 | Nexletol |
| Medtronic, INC. | $47.21 | 2024-2025 | Minimed 780g |
| Horizon Therapeutics Plc | $38.87 | 2019-2021 | |
| Viatris Specialty LLC | $38.46 | 2025 | Yupelri |
| Exact Sciences Corporation | $33.71 | 2023-2025 | Cologuard Collection Kit |
| Cipher Pharmaceuticals US LLC | $31.10 | 2025 | Spinosad, Natroba |
| Insulet Corporation | $28.50 | 2025 | Omnipod |
| Currax Pharmaceuticals LLC | $26.25 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $23.11 | 2024 | Edarbyclor |
| Rgh Enterprises LLC | $22.29 | 2024 | |
| Celgene Corporation | $20.12 | 2019 | |
| Dynavax Technologies Corporation | $19.96 | 2023 | Heplisav-B |
| Vistapharm, INC. | $19.29 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.40 | 2023 | Quviviq |
| Inspire Medical Systems, INC. | $16.99 | 2024 | Inspire |
| Scpharmaceuticals INC. | $15.78 | 2024 | |
| Endo Pharmaceuticals INC. | $14.99 | 2020 | |
| Ascensia Diabetes Care US INC. | $14.74 | 2025 | |
| Melinta Therapeutics, LLC | $14.57 | 2019 | |
| Genentech USA, INC. | $14.48 | 2020 | |
| Optinose US, INC. | $14.11 | 2021 | |
| Scilex Pharmaceuticals INC. | $13.00 | 2019 | |
| Neurocrine Biosciences, INC. | $12.99 | 2023 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $11.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shreeniwas Lele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.